Precision BioSciences Inc at Truist Securities Life Sciences Summit (April Series) Transcript
Good morning, everyone, and thanks for joining us for our conference call with Precision BioSciences. Before we begin, I need to read the following disclaimer. This call is arranged by Truist Securities Research for use by institutional investors and issuer clients as defined by FINRA. If you're not an institutional investor or issuer client, please disconnect at this time. For the required disclosures, please see our website at Truist Securities or our research library.
On today's call, we have on CSO and Co-Founder, Derek Jantz and Alex Kelly with us from Precision BioSciences. And for the audience zooming in, you can e-mail me questions at [email protected] and I will be happy to ask those questions for you.
So gentlemen, thanks for spending your time with us. And I know you have a lot going on with clinical trials and et cetera, but I'd be remiss not to ask about the CEO transition. Matt Kane, the current CEO is a Co-Founder and has been a key member of the team, but it was disclosed just a few days ago that he will be exiting the role. So
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |